Alnylam Pharma

Forecast & Rating29 analysts currently cover Alnylam Pharma, with about 75.9% giving a positive rating — meaning they expect the stock to rise. The average price target is $371.35, about 55.9% upside from the current price of $238.27. Price targets range from $256.00 to $536.00 — a wide spread, showing clear disagreement over just how much Alnylam Pharma can rise. Historically, about 100.0% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Alnylam Pharma closely still see room for the stock to rise. Data as of Sep 14, 2026; for reference only and not investment advice.